Stocks · Health care · Pharmaceutical Preparations

PUMA BIOTECHNOLOGY, INC.

PBYI Clue Score62
United States Fiscal year ends December CIK 0001401667 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Alessandra Cesano
14 Sep 2026
Director
Sold after exercise
62,150
$9.12
$566.99K
Richard Paul Bryce
29 Sep 2017
Sr VP, Clinical Research & Dev
Sold after exercise
15,000
$120.00
$1.80M
Richard Paul Bryce
7 Sep 2017
Sr VP, Clinical Research & Dev
Sold after exercise
14,000
$100.10
$1.40M
Richard Paul Bryce
6 Sep 2017
Sr VP, Clinical Research & Dev
Sold after exercise
1,000
$100.00
$100.00K
Showing 250 of 292 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 361
Amendments (4/A) skipped 7
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 63
Sales straight out of an exercise 5
Sales at will 224
Transactions with no price 0
Shares from compensation/vesting 6,205,640
Sales filed before the plan box existed 221
History held since 6 Oct 2011